Danaher operates within the global life sciences, diagnostics, and biotechnology industries - sectors that have exhibited strong secular growth and innovation despite cyclical fluctuations. From 2019 to 2023, the global molecular diagnostics market grew 2.5 times, while monoclonal antibody (mAb) production volumes rose at a double-digit compound annual rate. The company notes that more than 20 000 biologic therapies are now in development compared to ~600 approved by the FDA, and cell- and gene-therapy programs have expanded more than tenfold since 2015. Aging demographics (expected to surpass 1.5 billion people over 65 by 2050) and the continued shift from chemical drugs to biologics reinforce robust long-term demand for Danaher’s bioprocessing, analytical, and diagnostic technologies.
The industry’s near-term picture, however, reflects post-pandemic normalization. In 2024, the company core revenue declined 1.5 %, largely due to weaker demand in China and bioprocessing inventory destocking, while developed-market sales rose 2 %. Diagnostics outperformed on resilient clinical demand, while biotechnology and life sciences softened temporarily.
According to Deloitte’s 2025 Life Sciences Outlook, the sector remains largely optimistic despite volatility and competitive pressures. About 75% of global life sciences executives expect revenue and margin growth in 2025, driven by advances in digital transformation, AI adoption, and scientific innovation. The industry’s priorities are shifting toward R&D productivity and technology integration—nearly 60% of companies plan to expand generative AI investments across the value chain, aiming to accelerate research, streamline operations, and enhance decision-making. However, executives also anticipate headwinds from pricing pressure, expiring patents, regulatory changes, and supply chain risks.
Deloitte 2025 life sciences outlook
Danaher focuses into three segments - Biotechnology, Life Sciences, and Diagnostics - all structured by the Danaher Business System (DBS). In 2024, Biotechnology contributed roughly $6.8 billion, Life Sciences about $7.3 billion, and Diagnostics around $9.8 billion.
The Biotechnology segment helps customers manufacture high-quality, innovative therapies quickly, safely, and sustainably, accelerating access to new treatment options for patients. Its main brands Cytiva and Aldevron, provides end-to-end bioprocessing solutions - from cell-culture media and single-use technologies to purification systems - used in developing and producing biologic drugs. Cytiva (acquired from GE Life Sciences in March 2020) alone supports over 90% of global monoclonal antibody (mAb) manufacturing, with more than 75% of its revenue tied to antibody production.
The Life Sciences segment enables customers to reduce the time and cost needed to discover and develop life-changing therapies. It offers genomics, proteomics, and analytical-instrumentation technologies that help researchers study complex biological systems and develop new therapies faster and more efficiently, and benefits from more than 60% recurring revenue.
In Diagnostics, the company empowers clinicians to match the right therapy to the right patient at the right time by delivering instruments, consumables, and software that allow healthcare providers to diagnose diseases more accurately and select the most effective treatments. It benefits from brands like Cepheid, Beckman Coulter, and Radiometer.
In 2024, Danaher generated $23.88 billion in revenue, remaining flat YoY, with an operating profit of $4.86 billion, representing a 20.4% margin. Net income reached $3.90 billion, or $5.29 per diluted share, while EBITDA totaled roughly $7.24 billion after accounting for $721 million in depreciation and $1.63 billion in amortization. ROA stood at about 4.8% and ROE at 7.6%. Capital expenditures amounted to $1.39 billion. Total debt sits at $16.0 billion against $49.6 billion in equity, resulting in a conservative net-debt-to-capital ratio of roughly 22%.
Looking ahead, revenue is projected to increase 3.4% in 2025 to $24.7 billion, with continued recovery in bioprocessing and resilient demand in diagnostics and life sciences instrumentation. EBITDA is forecast to rise 7% to $7.72 billion, while the EBITDA margin should expand slightly to 31.3%. EBIT is expected to reach $6.97 billion, maintaining a 28.2% margin, while net income remains steady at $3.9 billion before growing toward $5.2 billion by 2026.
ROA is set to climb from 4.8% in 2024 to 6.2% in 2025 and ROE rising from 7.6% to nearly 10.9%. Net debt is expected to fall sharply, with leverage declining from 1.5x EBITDA in 2025 to below 1x by 2026, supported by robust FCF generation and a conservative capital structure.
In Q2 2025, revenue rose 3.5% YoY to $5.94 billion, with core sales up 1.5%. Growth was led by a 6% increase in Biotechnology, driven by renewed demand in bioprocessing and single-use technologies under Cytiva and Aldevron, offsetting softer performance in Life Sciences (–2.5%) and modest 2% growth in Diagnostics. Operating profit declined to $760 million from $1.17 billion a year earlier due to a $432 million pretax impairment in Life Sciences and facility write-downs in Biotechnology. Net earnings were $555 million compared with $907 million in the prior year while adjusted EPS rose 5% to $1.80. Cash generation remained a bright spot, with $1.34 billion in operating cash flow and $1.09 billion in FCF and the management reaffirmed its outlook for approximately 3% core revenue growth in 2025 and raised adjusted EPS guidance to $7.70–$7.80.
Danaher competes with major players such as Thermo Fisher Scientific, Agilent Technologies, and Illumina - with Thermo Fisher leading in life sciences tools and bioprocessing, Agilent in analytical instrumentation, and Illumina in genomics. Other competitors include Bio-Rad Laboratories and Sartorius in bioprocessing technologies, as well as Abbott and Johnson & Johnson in diagnostics and healthcare solutions.
Danaher faces risks from slowing global growth, inflation, and regulatory uncertainty in key markets like the U.S. and China, which can pressure pricing and demand. Competition in biotech and diagnostics remains intense, requiring sustained R&D investment, while supply chain and data security risks add operational complexity. Still, its strong balance sheet, recurring revenue, and diversified portfolio help cushion the impact of these challenges.
Danaher has re-emerged from its portfolio transformation as a pure-play life-sciences and diagnostics leader with structural advantages: a high recurring-revenue base, disciplined execution through DBS, and exposure to some of the fastest-growing segments of health science. Despite transient pressures in bioprocessing and China, the company is returning to growth with a strong cash profile and ample capacity for targeted M&A. Its secular drivers such as biologics, molecular diagnostics, and precision medicine accelerating, the group seems well positioned for continuous growth. /*contenu à centrer*/
